Non-Hodgkin Lymphoma

Increased potential cure for people with aggressive blood cancer

Published in Cancer Weekly, June 24th, 2003

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting showed that patients with an aggressive form of the blood cancer non-Hodgkin lymphoma (NHL), who were treated with MabThera plus standard chemotherapy (CHOP), have an improved chance of survival after 3 years compared with those treated with standard chemotherapy alone.

These results offer significant hope for people with the aggressive form of NHL, one of the most common types of blood cancer of the lymphatic system. Current medical opinion indicates that if patients survive past the 2-year landmark their chance of a cure can be up to 90%.

Results from the pivotal GELA...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-06-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry